Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 235

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort

Open access
Papillon-Cavanagh, Simon, Doshi, Parul, Dobrin, Radu, Szustakowski, Joseph, Walsh, Alice M. · 2020 · ESMO Open

Abstract

Abstract Importance Understanding the mechanisms of primary resistance to immune checkpoint blockade therapy is of paramount importance for treatment selection. Somatic mutations in STK11 and KEAP1 , frequently co-mutated in nonsquamous non–small cell lung cancer, have been associated with poor response to immune checkpoint blockade. However, previous reports lack non–immune checkpoint blockade controls needed to properly ascertain the predictive nature of those biomarkers. Objective To evaluate the predictive vs prognostic effect of STK11 or KEAP1 mutations across different treatment classes in nonsquamous non–small cell lung cancer. Design A retrospective, real-world data cohort from the Flatiron Health network linked with genetic testing from Foundation Medicine, from January 1, 2011, through December 31, 2018. Setting Multicenter, including academic and community practices. Participants Patients diagnosed with stage IIIB, IIIC, IVA, or IVB nonsquamous non–small cell lung cancer who initiated first-line treatment within 90 days after diagnosis. Main Outcomes and Measures Real-world, progression-free survival and overall survival calculated from time of initiation of first-line treatment. Results We analyzed clinical and mutational data for 2276 patients with advanced, nonsquamous non–small cell lung cancer (mean age at advanced diagnosis, 66.3 years [SD 10.3], 54.4% female, 80.1% with a history of smoking), including patients treated with anti–programmed death-1/anti–programmed death ligand 1 inhibitors at first line (n = 574). Mutations in STK11 or KEAP1 were associated with poor outcomes across multiple therapeutic classes and were not specifically associated with poor outcomes in immune checkpoint blockade cohorts. There was no observable interaction between STK11 mutations and anti–programmed death-1/anti–programmed death ligand 1 treatment on real-world, progression-free survival (HR, 1.05; 95% CI, 0.76-1.44; P = .785) or overall survival (HR, 1.13; 95% CI, 0.76-1.67; P = .540). Similarly, there was no observable interaction between KEAP1 on real-world, progression-free survival (HR, 0.93; 95% CI, 0.67-1.28; P = .653) or overall survival (HR, 0.98; 95% CI, 0.66-1.45; P = .913). Results were consistent in KRAS -mutated patients. Conclusion and Relevance Our results show that STK11 - KEAP1 mutations are prognostic, not predictive, biomarkers for anti–programmed death-1/anti–programmed death ligand 1 therapy. Key Points Question Are loss-of-function somatic mutations in STK11 and KEAP1 predictive of response to immune checkpoint blockade or simply prognostic? Findings In this observational real-world cohort totaling 2276 patients, including 574 treated with immune checkpoint blockade, we find that mutations in STK11 and KEAP1 are associated with poor prognosis across multiple first-line treatment classes. Meaning Mutations in STK11 and KEAP1 are prognostic biomarkers of poor response to both immune checkpoint blockade and chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/esmoopen-2020-000706

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 235

Metadata

Authors
Papillon-Cavanagh, S., Doshi, P., Dobrin, R., Szustakowski, J., & Walsh, A. M.
Venue
ESMO Open
Publisher
Elsevier BV
Published
2020
Volume
5
Issue
2
Pages
e000706
ISSN
2059-7029 (ISSN-L)
OpenAlex
W3017125932
Cited by
235
References
8
FWCI
17.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort. https://app.cochat.ai/papers/10.1136/esmoopen-2020-000706
The paper
Papillon-Cavanagh, S., Doshi, P., Dobrin, R., Szustakowski, J., & Walsh, A. M. (2020). STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort. ESMO Open. https://doi.org/10.1136/esmoopen-2020-000706

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.